mAbxience and Egis Enter Strategic License Agreement for Biosimilar Candidates in Key Central and Eastern European MarketsMiguel Martínez-Cava2024-11-12T08:59:05+01:00November 12, 2024|Read More
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar CandidateMiguel Martínez-Cava2024-10-03T14:33:04+02:00October 3, 2024|Read More
mAbxience Appoints Jurgen Van Broeck as New CEOMiguel Martínez-Cava2024-05-09T09:42:26+02:00May 9, 2024|Read More
mAbxience and Teva Announce Strategic Global Licensing Agreement for Oncology Biosimilar CandidateMiguel Martínez-Cava2024-04-04T14:38:15+02:00April 4, 2024|Read More
mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry DiseaseMiguel Martínez-Cava2024-02-05T11:58:27+01:00February 5, 2024|Read More
mAbxience Announces Licensing Agreement with Intas Pharmaceuticals Ltd. for Etanercept Biosimilar Targeting Autoimmune Diseases in more than 150 Countries, including Europe and the United States of AmericaMiguel Martínez-Cava2023-12-20T10:49:24+01:00December 20, 2023|Read More
mAbxience and Abdi İbrahim Announce Landmark Technology Transfer Agreement, Advancing Biotechnology in TürkiyeMiguel Martínez-Cava2023-11-20T08:43:23+01:00November 20, 2023|Read More
mAbxience and MS Pharma Sign Partnership for Denosumab Biosimilar in Select MEA CountriesMiguel Martínez-Cava2023-11-13T07:53:41+01:00November 13, 2023|Read More
mAbxience and Amneal Strengthen Alliance with Two Denosumab Biosimilars in the U.S. for the Treatment of Oncology and Bone DiseasesClara Prieto2023-10-21T14:44:19+02:00October 12, 2023|Read More
mAbxience and Abbott Sign Strategic Agreement to Broaden Access to a Pipeline of Biosimilars in Key Emerging MarketsMiguel Martínez-Cava2023-10-05T16:05:09+02:00September 20, 2023|Read More
